Literature DB >> 25922694

Clinical implications and future perspectives in testing non-small cell lung cancer (NSCLC) for anaplastic lymphoma kinase (ALK) gene rearrangements.

Francesco Gelsomino1, Giulio Rossi1, Marcello Tiseo1.   

Abstract

Entities:  

Year:  2015        PMID： 25922694      PMCID： PMC4387395          DOI： 10.3978/j.issn.2072-1439.2015.01.32

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  20 in total

1.  Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH.

Authors:  Eunhee S Yi; Jennifer M Boland; Joseph J Maleszewski; Anja C Roden; Andre M Oliveira; Marie-Christine Aubry; Michele R Erickson-Johnson; Bolette L Caron; Yan Li; Hui Tang; Shawn Stoddard; Jason Wampfler; Kimary Kulig; Ping Yang
Journal:  J Thorac Oncol       Date:  2011-03       Impact factor: 15.609

2.  Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a French study.

Authors:  Anne McLeer-Florin; Denis Moro-Sibilot; Adrien Melis; Dimitri Salameire; Christine Lefebvre; Françoise Ceccaldi; Florence de Fraipont; Elisabeth Brambilla; Sylvie Lantuejoul
Journal:  J Thorac Oncol       Date:  2012-02       Impact factor: 15.609

3.  Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung cancer.

Authors:  D Ross Camidge; Mariana Theodoro; Delee A Maxson; Margaret Skokan; Tara O'Brien; Xian Lu; Robert C Doebele; Anna E Barón; Marileila Varella-Garcia
Journal:  Cancer       Date:  2012-01-26       Impact factor: 6.860

4.  A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry.

Authors:  Mari Mino-Kenudson; Lucian R Chirieac; Kenny Law; Jason L Hornick; Neal Lindeman; Eugene J Mark; David W Cohen; Bruce E Johnson; Pasi A Jänne; A John Iafrate; Scott J Rodig
Journal:  Clin Cancer Res       Date:  2010-02-23       Impact factor: 12.531

5.  Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.

Authors:  Shirish M Gadgeel; Leena Gandhi; Gregory J Riely; Alberto A Chiappori; Howard L West; Michele C Azada; Peter N Morcos; Ruey-Min Lee; Linta Garcia; Li Yu; Frederic Boisserie; Laura Di Laurenzio; Sophie Golding; Jotaro Sato; Shumpei Yokoyama; Tomohiro Tanaka; Sai-Hong Ignatius Ou
Journal:  Lancet Oncol       Date:  2014-08-18       Impact factor: 41.316

Review 6.  Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer.

Authors:  Marcello Tiseo; Francesco Gelsomino; Marco Bartolotti; Paola Bordi; Melissa Bersanelli; Giulio Rossi; Andrea Ardizzoni
Journal:  Expert Rev Anticancer Ther       Date:  2011-11       Impact factor: 4.512

7.  Histologic subtypes, immunohistochemistry, FISH or molecular screening for the accurate diagnosis of ALK-rearrangement in lung cancer: a comprehensive study of Caucasian non-smokers.

Authors:  Pierre-Alexandre Just; Aurélie Cazes; Anne Audebourg; Anatole Cessot; Karine Pallier; Claire Danel; Marie-Cécile Vacher-Lavenu; Pierre Laurent-Puig; Benoît Terris; Hélène Blons
Journal:  Lung Cancer       Date:  2011-12-06       Impact factor: 5.705

8.  Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization.

Authors:  Jin Ho Paik; Gheeyoung Choe; Hyojin Kim; Ji-Young Choe; Hyun Ju Lee; Choon-Taek Lee; Jong Seok Lee; Sanghoon Jheon; Jin-Haeng Chung
Journal:  J Thorac Oncol       Date:  2011-03       Impact factor: 15.609

9.  First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

Authors:  Benjamin J Solomon; Tony Mok; Dong-Wan Kim; Yi-Long Wu; Kazuhiko Nakagawa; Tarek Mekhail; Enriqueta Felip; Federico Cappuzzo; Jolanda Paolini; Tiziana Usari; Shrividya Iyer; Arlene Reisman; Keith D Wilner; Jennifer Tursi; Fiona Blackhall
Journal:  N Engl J Med       Date:  2014-12-04       Impact factor: 91.245

10.  Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project.

Authors:  Fiona H Blackhall; Solange Peters; Lukas Bubendorf; Urania Dafni; Keith M Kerr; Henrik Hager; Alex Soltermann; Kenneth J O'Byrne; Christoph Dooms; Aleksandra Sejda; Javier Hernández-Losa; Antonio Marchetti; Spasenija Savic; Qiang Tan; Erik Thunnissen; Ernst-Jan M Speel; Richard Cheney; Daisuke Nonaka; Jeroen de Jong; Miguel Martorell; Igor Letovanec; Rafael Rosell; Rolf A Stahel
Journal:  J Clin Oncol       Date:  2014-07-28       Impact factor: 44.544
View more
  3 in total

1.  siRNA targeting of Trop2 suppresses the proliferation and invasion of lung adenocarcinoma H460 cells.

Authors:  Xiao-Yan Gao; Ye-Han Zhu; Li-Xin Zhang; Hui-Yu Lu; Ai-Gui Jiang
Journal:  Exp Ther Med       Date:  2015-05-28       Impact factor: 2.447

Review 2.  Tackling ALK in non-small cell lung cancer: the role of novel inhibitors.

Authors:  Francesco Facchinetti; Marcello Tiseo; Massimo Di Maio; Paolo Graziano; Emilio Bria; Giulio Rossi; Silvia Novello
Journal:  Transl Lung Cancer Res       Date:  2016-06

3.  A study of therapy targeted EGFR/ALK mutations in Indian patients with lung adenocarcinoma: A clinical and epidemiological study.

Authors:  Vandana Rana; Praveer Ranjan; Rajat Jagani; K R Rathi; Dharmesh Kumar; Anurag Khera
Journal:  Med J Armed Forces India       Date:  2017-11-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.